Johnson & Johnson's data for two cancer drugs wins praise. Why does JPMorgan still rate the stock Neutral?
Riptac showed potential for efficacy and tolerability in prostate cancer patients who had received multiple prior lines of treatment, while Rybrevant offers a new opportunity in head and neck cancer. But Johnson & Johnson already trades at a premium valuation of 21 times expected 2027 earnings per share, limiting its relative upside in JPMorgan's view.
Original source：J.P. MorganFirst published on Unhidea：Original source date：
Key takeaway
JPMorgan believes Johnson & Johnson's oncology pipeline can expand its long-term growth opportunity, but further development and a premium valuation remain two hurdles between early clinical progress and the stock's current appeal.
Why is JPMorgan encouraged by the Riptac data?
The highlight of JNJ-6143 (Halda Riptac) is its potential for both efficacy and tolerability in patients with advanced disease who have received multiple prior lines of treatment. The phase I trial involved patients with metastatic castration-resistant prostate cancer who had received at least one androgen receptor pathway inhibitor (ARPI); participants had previously received a median of 4 lines of systemic treatment.
In the 50 mg group selected for the phase II study, the objective response rate was 75%: the proportion of patients whose tumors shrank according to the trial criteria. At 5.6 months of follow-up, 71% of patients remained on treatment. The study also observed drug activity in patients with different genomic characteristics.
There were no grade 3 or higher treatment-related adverse events in the same dose group. JPMorgan therefore sees the drug's differentiation potential as stemming from both efficacy and tolerability; these assessments relate to the phase I study and the current follow-up window.
How can the prostate cancer opportunity expand beyond later-line treatment?
Johnson & Johnson is advancing Riptac into phase III for metastatic castration-resistant prostate cancer after ARPI treatment, while also exploring hormone-sensitive prostate cancer and combination therapies. The path to a larger commercial opportunity runs from the current later-line patient population to broader disease stages and treatment combinations.
JPMorgan sees Riptac and KLK2-related programs as part of Johnson & Johnson's prostate cancer portfolio and believes they could create a substantial opportunity in the 2030s. Early clinical signals and development plans currently support that view; subsequent phase III studies and indication expansion will determine the scope of the opportunity.
What opportunity does Rybrevant add in head and neck cancer?
In cohort 5 of the OrigAMI-4 phase I/II trial, Rybrevant was combined with Keytruda and chemotherapy as a first-line treatment, achieving an objective response rate of 77% among 22 patients with HPV-unrelated head and neck cancer. JPMorgan therefore remains optimistic about its role in this population.
The comparator cited in the report is an objective response rate of 36% for Keytruda plus chemotherapy in a population with a PD-L1 combined positive score (CPS) of ≥1. The data come from different studies, and the stated population criteria also differ, so the gap should be understood in the context of each study.
On development progress, Johnson & Johnson has submitted an application for Rybrevant as a second-line indication in head and neck cancer, and a first-line phase III study is underway: the second-line indication is under regulatory review, while the first-line use continues along the clinical development path.
Why hasn't the positive pipeline news resulted in a more favorable rating?
JPMorgan remains positive on Johnson & Johnson's overall operations: its innovative medicines business continues to grow at a high-single-digit rate, while its medtech portfolio continues to shift toward faster-growing areas, supporting the company's sustained growth.
The constraint is price. Johnson & Johnson trades at approximately 21 times expected 2027 earnings per share. JPMorgan believes it already commands a premium and has more limited share-price upside than its peers, so it maintains a Neutral rating. Pipeline progress strengthens the long-term business outlook, but valuation limits the bank's assessment of potential stock returns.
